Finerenone is indicated to delay progression of kidney disease and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) and hospitalization for heart failure in adults with chronic kidney disease (CKD) and type 2 diabetes (T2D).

Adjuvant treatment of adult patients with RCC at intermediate-high or
high risk of recurrence following nephrectomy, or following nephrectomy and
resection of metastatic lesions.

Tafasitamab is indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, who are not eligible for autologous stem cell transplant (ASCT).

RINVOQ is indicated for the treatment of adults and adolescents 12 years of age and older with refractory moderate to severe atopic dermatitis (AD) who are not adequately controlled with a systemic treatment (e.g., steroid or biologic) or when use of those therapies is inadvisable.RINVOQ can be used with or without topical corticosteroids.

For the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy.

Pembrolizumab
in combination with chemotherapy with or without bevacizumab, for the
treatment of adult patients with persistent, recurrent, or metastatic cervical
cancer whose tumors express PD-L1 (CPS=1) as determined by a validated
test.

Treatment of adult and adolescent patients 12 years of age and older with differentiated thyroid carcinoma (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory or ineligible.

Pembrolizumab is indicated for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB or IIC melanoma following complete resection.

As replacement therapy for primaryhumoral immunodeficiency (PI) and secondary humoralimmunodeficiency (SI) in adult patients.